New Genedata Profiler Release Strengthens Data Security and Patient Privacy in Translational Research
Genedata Profiler Release 10.0 addresses global regulatory requirements with triple-layer data security and bolstered patient privacy; delivers on scientific goals for translational research on data from both clinical and pre-clinical settings
April 5, 2016
Boston, MA, USA
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the launch of Release 10.0 of Genedata Profiler, its open, interoperable enterprise software platform for precision medicine designed to facilitate efficient omics-based patient and compound profiling processes. With its strong focus on data security and patient privacy, Release 10.0 addresses translational researchers’ concerns about rapidly-changing and often confusing global regulatory demands.
Genedata Profiler Release 10.0 is study-centric, with user roles defined for each research study and data organized and securely contained at the study level within the software. Genedata Profiler integrates and federates omic and phenotypic data from globally-distributed storage facilities, performs automated data quality assessment (QC) and produces standardized reports. Furthermore, the software comes with user-friendly interfaces and interactive visualizations that allow scientists to quickly identify clinically relevant results. With this release in particular, the chain of custody of data has been strengthened to ensure that research data is traceable and reproducible.
The Genedata Profiler platform extends the level of data security to three layers:
- a new study layer allowing permissions to be defined by scientific role for each research study. For example, an NGS expert can set up a workflow while biologists and analysts on the study team are restricted only to executing it; deletion of data may be authorized for certain defined user roles but not for others;
- an operational layer, with permissions set according to organizationally-defined levels such as Administrator, Manager and User; and
- a physical layer of security which maintains user permissions for data federated from multiple sources, including external file systems.
Supporting high performance computer clusters, Release 10.0 of Genedata Profiler marries data security with performance. The interoperable software platform easily integrates with third party middle-layer software systems such as iRODS, and its out-of-the-box integration with Active Directory/LDAP reduces software set-up and implementation costs.
“Release 10.0 is the ‘Security Release’ of Genedata Profiler,” commented Dr Othmar Pfannes, CEO of Genedata. “With this latest version of our cutting-edge software for genomic profiling of patients, Genedata has produced a truly security-hardened enterprise solution for research involving omic data from patients in both clinical and less-regulated research environments. Genedata Profiler has cemented its position as the software platform of choice for effective and efficient translational research that delivers on scientific goals while protecting data privacy.”
Genedata scientists are demonstrating Release 10.0 of Genedata Profiler at Booth #335 at Bio-IT World Conference & Expo in Boston, MA, from April 5–7.
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.